Literature DB >> 15687722

Rational surveillance programs for early stage breast cancer patients after primary treatment.

Joseph A Mollick1, Robert W Carlson.   

Abstract

The majority of women with early stage breast cancers are successfully treated with surgery, radiation therapy and adjuvant systemic therapy. However, 30% of all Stage I and Stage II patients can be expected to experience a relapse. The belief that early detection of recurrences can lead to an increase in survival has been used to justify intensive follow-up regimens following primary treatment of patients with early stage disease. However, the vast majority of data support a program of scheduled surveillance visits and demonstrate that a comprehensive history and physical examination is as efficacious as programs utilizing intensive testing and imaging procedures in the asymptomatic patient. Screening mammography to detect ipsilateral in-breast recurrence or a new primary cancer in the contralateral breast is the only imaging study that is recommended for routine surveillance. Knowledge of the natural history of breast cancer, risk factors for relapse, and the symptoms and physical findings commonly associated with recurrence are central to efficiently and effectively monitoring this cohort of women in clinical practice.

Entities:  

Mesh:

Year:  2004        PMID: 15687722     DOI: 10.3233/bd-2004-21107

Source DB:  PubMed          Journal:  Breast Dis        ISSN: 0888-6008


  3 in total

1.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

Authors:  Rupert Bartsch; Andrea Rottenfusser; Catharina Wenzel; Karin Dieckmann; Ursula Pluschnig; Gabriela Altorjai; Margaretha Rudas; Robert M Mader; Richard Poetter; Christoph C Zielinski; Guenther G Steger
Journal:  J Neurooncol       Date:  2007-06-08       Impact factor: 4.130

2.  Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.

Authors:  Y H Park; M J Park; S H Ji; S Y Yi; D H Lim; D H Nam; J-I Lee; W Park; D H Choi; S J Huh; J S Ahn; W K Kang; K Park; Y-H Im
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

3.  Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

Authors:  Rupert Bartsch; Catharina Wenzel; Dagmar Hussian; Ursula Pluschnig; Ursula Sevelda; Wolfgang Koestler; Gabriela Altorjai; Gottfried J Locker; Robert Mader; Christoph C Zielinski; Guenther G Steger
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.